These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 7087963)

  • 1. Effect of lipids, structural precursors of lipids and fatty acids on complement-mediated killing of antibody-sensitized nucleated cells.
    Ohanian SH; Schlager SI; Saha S
    Mol Immunol; 1982 Apr; 19(4):535-42. PubMed ID: 7087963
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of specific phospholipids on the antibody-complement-mediated killing of nucleated cells.
    Ohanian SH; Schlager SI; Yamazaki M; Ishida B
    J Immunol; 1979 Sep; 123(3):1014-9. PubMed ID: 469242
    [No Abstract]   [Full Text] [Related]  

  • 3. Correlation between the ability of tumor cells to incorporate specific fatty acids and their sensitivity to killing by a specific antibody plus guinea pig complement.
    Schlager SI; Ohanian SH; Borsos T
    J Natl Cancer Inst; 1978 Sep; 61(3):931-4. PubMed ID: 278869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma membrane and intracellular lipid synthesis in tumor cells rendered resistant to humoral immune killing after treatment with hormones.
    Schlager SI; Ohanian SH
    J Natl Cancer Inst; 1980 Apr; 64(4):943-50. PubMed ID: 6988626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humoral immune killing of nucleated cells: mechanisms of complement-mediated attack and target cell defense.
    Ohanian SH; Schlager SI
    Crit Rev Immunol; 1981 Jan; 1(3):165-209. PubMed ID: 6174273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A role for fatty acid composition of complex cellular lipids in the susceptibility of tumor cells to humoral immune killing.
    Schlager SI; Ohanian SH
    J Immunol; 1979 Jul; 123(1):146-52. PubMed ID: 448144
    [No Abstract]   [Full Text] [Related]  

  • 7. Stimulation of the synthesis and release of lipids in tumor cells under attack by antibody and C.
    Schlager SI; Ohanian SH; Borsos T
    J Immunol; 1978 Mar; 120(3):895-901. PubMed ID: 632591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytolysis of Sendai virus-infected guinea-pig cells by homologous complement.
    Okada H; Tanaka H; Okada N
    Immunology; 1983 May; 49(1):29-35. PubMed ID: 6301976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of lipid fatty acyl composition and membrane fluidity in the resistance of Acholeplasma laidlawii to complement-mediated killing.
    Dahl JS; Dahl CE; Levine RP
    J Immunol; 1979 Jul; 123(1):104-8. PubMed ID: 448140
    [No Abstract]   [Full Text] [Related]  

  • 10. Tumor cell lipid composition and sensitivity to humoral immune killing. II. Influence of plasma membrane and intracellular lipid and fatty acid content.
    Schlager SI; Ohanian SH
    J Immunol; 1980 Aug; 125(2):508-17. PubMed ID: 7391566
    [No Abstract]   [Full Text] [Related]  

  • 11. Physico-chemical properties of tumor cells that influence their susceptibility to humoral immune killing.
    Schlager SI; Ohanian SH
    Biochem Biophys Res Commun; 1979 Dec; 91(4):1512-20. PubMed ID: 526320
    [No Abstract]   [Full Text] [Related]  

  • 12. Mechanisms of dietary fat modulation of tumorigenesis: changes in immune response.
    Erickson KL
    Prog Clin Biol Res; 1986; 222():555-86. PubMed ID: 3538047
    [No Abstract]   [Full Text] [Related]  

  • 13. Complement-mediated killing of myeloma tumour cells: differences in susceptibility to lysis by antibodies and complement are independent of antigen expression and antibody binding.
    Celis B; Celis E
    Immunology; 1983 Jun; 49(2):321-8. PubMed ID: 6343234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of lipids synthesized and released by tumor cells under attack by antibody and complement.
    Schlager SI; Ohanian SH; Borsos T
    J Immunol; 1978 May; 120(5):1644-50. PubMed ID: 659869
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of hormones on the killing by antibody and complement of tumor cells treated with proteolytic enzymes.
    Schlager SI; Ohanian SH; Borsos T
    Immunopharmacology; 1979 Mar; 1(2):115-24. PubMed ID: 400472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of antibody-complement-mediated killing of tumor cells by hormones.
    Schlager SI; Ohanian SH; Borsos T
    Cancer Res; 1976 Oct; 36(10):3672-7. PubMed ID: 182362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homologous species restriction of the complement-mediated killing of nucleated cells.
    Yamamoto H; Blaas P; Nicholson-Weller A; Hänsch GM
    Immunology; 1990 Aug; 70(4):422-6. PubMed ID: 1697561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor cell killing by macrophages activated in vitro with lymphocyte mediators. 5. Role of proteases, inhibitors, and substrates.
    Piessens WF; Sharma SD
    Cell Immunol; 1980 Dec; 56(2):286-91. PubMed ID: 6781762
    [No Abstract]   [Full Text] [Related]  

  • 19. Relationship between the intracellular cyclic adenosine 3':5'-monophosphate level of tumor cells and their sensitivity to killing by antibody and complement.
    Lo TN; Boyle MD
    Cancer Res; 1979 Aug; 39(8):3156-62. PubMed ID: 222445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity.
    Guo B; Ma ZW; Li H; Xu GL; Zheng P; Zhu B; Wu YZ; Zou Q
    Clin Immunol; 2008 Aug; 128(2):155-63. PubMed ID: 18502181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.